HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies
HSF1通路抑制剂临床候选药物(CCT361814/NXP800)基于表型筛选开发,有望用于治疗难治性卵巢癌和其他恶性肿瘤。
期刊:Journal of Medicinal Chemistry
影响因子:6.8
doi:10.1021/acs.jmedchem.3c00156
Pasqua, A Elisa; Sharp, Swee Y; Chessum, Nicola E A; Hayes, Angela; Pellegrino, Loredana; Tucker, Michael J; Miah, Asadh; Wilding, Birgit; Evans, Lindsay E; Rye, Carl S; Mok, N Yi; Liu, Manjuan; Henley, Alan T; Gowan, Sharon; De Billy, Emmanuel; Te Poele, Robert; Powers, Marissa; Eccles, Suzanne A; Clarke, Paul A; Raynaud, Florence I; Workman, Paul; Jones, Keith; Cheeseman, Matthew D